- PA1-338 - Invitrogen Antibodies SREBF2 antibody

Submitted references N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism.

Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L, Tian Y, Yi C, Fan Z
Nature communications 2021 Nov 2;12(1):6314

Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites.

Bosc C, Broin N, Fanjul M, Saland E, Farge T, Courdy C, Batut A, Masoud R, Larrue C, Skuli S, Espagnolle N, Pagès JC, Carrier A, Bost F, Bertrand-Michel J, Tamburini J, Récher C, Bertoli S, Mansat-De Mas V, Manenti S, Sarry JE, Joffre C
Nature communications 2020 Aug 13;11(1):4056

Absence of gravin-mediated signaling inhibits development of high-fat diet-induced hyperlipidemia and atherosclerosis.

Fan Q, Yin X, Rababa'h A, Diaz Diaz A, Wijaya CS, Singh S, Suryavanshi SV, Vo HH, Saeed M, Zhang Y, McConnell BK
American journal of physiology. Heart and circulatory physiology 2019 Oct 1;317(4):H793-H810

p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C
Cell 2019 Jan 24;176(3):564-580.e19

Pleiotropic Role of p53 in Injury and Liver Regeneration after Acetaminophen Overdose.

Borude P, Bhushan B, Gunewardena S, Akakpo J, Jaeschke H, Apte U
The American journal of pathology 2018 Jun;188(6):1406-1418

High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease.

Huster D, Purnat TD, Burkhead JL, Ralle M, Fiehn O, Stuckert F, Olson NE, Teupser D, Lutsenko S
The Journal of biological chemistry 2007 Mar 16;282(11):8343-55

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of SREBP2 (green) showing staining in the cytoplasm of HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a SREBP2 polyclonal antibody (Product # PA1-338) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of SREBP2 (green) showing staining in the cytoplasm of L6 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a SREBP2 polyclonal antibody (Product # PA1-338) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of SREBP2 (green) showing staining in the cytoplasm of PC12 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a SREBP2 polyclonal antibody (Product # PA1-338) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4 ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 PPARdelta promotes liver CSC self-renewal via enhancing cholesterol synthesis. a Heatmap analysis of signature molecules of steroid metabolites under positive ion mode in PPARdelta depleted versus sgCtrl treated liver CSC cells. b Heatmap analysis of cholesterol metabolism related genes in PPARdelta-depleted and control CSCs. Data were normalized to endogenous 18S rRNA expression and sgCtrl were assigned with a value of 1. c Kaplan-Meier plots of overall survival for SREBF2 in TMA cohort. Median expression value was used as a cut-off. P values for Kaplan-Meier curve were determined using a two-sided log-rank test. d Western blotting analysis of cholesterol metabolism related gene expression in PPARdelta depleted, GSK3787 (20 muM) treated and SREBF2 overexpressed liver CSCs compared with control CSCs. n = 3 biologically independent samples. e Levels of total cholesterol, free cholesterol and cholesterol esterin TRMT6/TRMT61A, PPARdelta, and SREBF2 depleted liver CSCs. Data are means +- SD. n = 6. Exact P values from left to right: 0.037, 0.0061, 0.0070, 0.0032, 0.046. f Filipin III staining of cellular cholesterol distributions in PPARdelta depleted, and co-transfection of SREBF2 in PPARdelta depleted liver CSCs from two HCC patients compared with control CSCs ( n = 5). Scale bar, 10 mum. n = 3 biologically independent samples. g Total cholesterol levels in liver CSCs treated with vehicle (DMSO), PPARdelta antagonist (GSK3787, 20 muM) or agonist (GW501516, 20 muM) for 7

PA1-338

Antibody data